Cargando…

Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation

BACKGROUND: Bupropion hydrochloride (Zyban) is an effective aid to smoking cessation; however, its use has previously been associated with neuropsychiatric adverse events. Here we report results of the patient Knowledge, Attitudes, and Behavior survey that forms part of the Year 7 Risk Evaluation an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascher, John, Stemhagen, Annette, Stender, Monika, Win, Beta, Winter, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119167/
https://www.ncbi.nlm.nih.gov/pubmed/30105744
http://dx.doi.org/10.1007/s40801-018-0140-2
_version_ 1783352034490056704
author Ascher, John
Stemhagen, Annette
Stender, Monika
Win, Beta
Winter, Christina
author_facet Ascher, John
Stemhagen, Annette
Stender, Monika
Win, Beta
Winter, Christina
author_sort Ascher, John
collection PubMed
description BACKGROUND: Bupropion hydrochloride (Zyban) is an effective aid to smoking cessation; however, its use has previously been associated with neuropsychiatric adverse events. Here we report results of the patient Knowledge, Attitudes, and Behavior survey that forms part of the Year 7 Risk Evaluation and Mitigation Strategy (REMS) assessment for Zyban. OBJECTIVE: Assess participants’ understanding of the neuropsychiatric risks associated with branded bupropion hydrochloride products that are used for smoking cessation, as described in the Medication Guides. METHODS: A cross-sectional study was conducted among patients ≥ 18 years of age, who had used or filled a prescription for branded bupropion hydrochloride for smoking cessation in the past 6 months. Participants were recruited through an online panel, pharmacy network, or by healthcare provider referral, and invited to complete a survey containing questions regarding the risks associated with the use of branded bupropion hydrochloride products, and whether they had received and read the Medication Guide. The study aimed for ≥ 80% of participants to respond correctly to each question regarding neuropsychiatric risks. RESULTS: From the 50,985 survey invitations distributed, 1017 participants responded, of whom 144 were eligible and 142 completed the survey. Over 80% of participants correctly responded to most neuropsychiatric risk questions. Approximately three-quarters of participants received the Medication Guide when they last filled their prescription, of whom over half read the Medication Guide at that time. CONCLUSIONS: Participants enrolled in this Year 7 REMS survey had good understanding of the neuropsychiatric risks associated with using branded bupropion hydrochloride products for smoking cessation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40801-018-0140-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6119167
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-61191672018-09-10 Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation Ascher, John Stemhagen, Annette Stender, Monika Win, Beta Winter, Christina Drugs Real World Outcomes Original Research Article BACKGROUND: Bupropion hydrochloride (Zyban) is an effective aid to smoking cessation; however, its use has previously been associated with neuropsychiatric adverse events. Here we report results of the patient Knowledge, Attitudes, and Behavior survey that forms part of the Year 7 Risk Evaluation and Mitigation Strategy (REMS) assessment for Zyban. OBJECTIVE: Assess participants’ understanding of the neuropsychiatric risks associated with branded bupropion hydrochloride products that are used for smoking cessation, as described in the Medication Guides. METHODS: A cross-sectional study was conducted among patients ≥ 18 years of age, who had used or filled a prescription for branded bupropion hydrochloride for smoking cessation in the past 6 months. Participants were recruited through an online panel, pharmacy network, or by healthcare provider referral, and invited to complete a survey containing questions regarding the risks associated with the use of branded bupropion hydrochloride products, and whether they had received and read the Medication Guide. The study aimed for ≥ 80% of participants to respond correctly to each question regarding neuropsychiatric risks. RESULTS: From the 50,985 survey invitations distributed, 1017 participants responded, of whom 144 were eligible and 142 completed the survey. Over 80% of participants correctly responded to most neuropsychiatric risk questions. Approximately three-quarters of participants received the Medication Guide when they last filled their prescription, of whom over half read the Medication Guide at that time. CONCLUSIONS: Participants enrolled in this Year 7 REMS survey had good understanding of the neuropsychiatric risks associated with using branded bupropion hydrochloride products for smoking cessation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40801-018-0140-2) contains supplementary material, which is available to authorized users. Springer International Publishing 2018-08-13 /pmc/articles/PMC6119167/ /pubmed/30105744 http://dx.doi.org/10.1007/s40801-018-0140-2 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research Article
Ascher, John
Stemhagen, Annette
Stender, Monika
Win, Beta
Winter, Christina
Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation
title Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation
title_full Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation
title_fullStr Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation
title_full_unstemmed Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation
title_short Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation
title_sort patient understanding of the neuropsychiatric risks associated with branded bupropion hydrochloride products used for smoking cessation
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119167/
https://www.ncbi.nlm.nih.gov/pubmed/30105744
http://dx.doi.org/10.1007/s40801-018-0140-2
work_keys_str_mv AT ascherjohn patientunderstandingoftheneuropsychiatricrisksassociatedwithbrandedbupropionhydrochlorideproductsusedforsmokingcessation
AT stemhagenannette patientunderstandingoftheneuropsychiatricrisksassociatedwithbrandedbupropionhydrochlorideproductsusedforsmokingcessation
AT stendermonika patientunderstandingoftheneuropsychiatricrisksassociatedwithbrandedbupropionhydrochlorideproductsusedforsmokingcessation
AT winbeta patientunderstandingoftheneuropsychiatricrisksassociatedwithbrandedbupropionhydrochlorideproductsusedforsmokingcessation
AT winterchristina patientunderstandingoftheneuropsychiatricrisksassociatedwithbrandedbupropionhydrochlorideproductsusedforsmokingcessation